Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Explore the full study to evaluate its impact on treatment algorithms and personalized care pathways: To view or add a comment, sign in New Evidence in Obesity Care A recent large-scale study from the Cleveland Clinic compared bariatric surgery with GLP-1 receptor agonists alone and the results are eye-opening: More sustained weight loss Greater reductions in cardiovascular risk Lower mortality rates This reinforces what many of us in the field have observed: Bariatric surgery isnt just about weight its about long-term health outcomes
The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg once weekly, which caters to individual patient needs Clinical implications : Beyond its primary use for type 2 diabetes, tirzepatide has been explored for its potential in treating obesity, osteoarthritis of the knee, atherosclerosis, and other metabolic diseases
Mass spec confirms the molecular weight matches the exact peptide sequence claimed on the label proving it is what it says it is, not a cheaper substitute
That broader approach matters because cardiovascular support usually is not just one thing
